Trials / Completed
CompletedNCT01846793
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Nymox Corporation · Industry
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of NX-1207.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NX-1207 | 2.5 mg NX-1207 in 10 mL saline vehicle |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2013-05-03
- Last updated
- 2017-03-10
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01846793. Inclusion in this directory is not an endorsement.